Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 18/20 | 0.48 |
| ▸ | FLT3 | P36888 | 15/20 | 0.48 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22466879 | 0.87 | CDK2 (0.49) | CDK2CCNA1FLT3PBKSTING1 | |
| SCHEMBL30490713 | 0.87 | CDK2 (0.49) | CDK2CCNA1FLT3PBKSTING1 | |
| SCHEMBL22477866 | 0.83 | CDK2 (0.58) | CDK2CCNA1FLT3PBKSTING1 | |
| SCHEMBL22467004 | 0.82 | CDK2 (0.46) | CDK2CCNA1FLT3PBK | |
| SCHEMBL30490709 | 0.82 | CDK2 (0.46) | CDK2CCNA1FLT3PBK | |
| SCHEMBL22477920 | 0.82 | CDK2 (0.59) | CDK2CCNA1FLT3PBKSTING1 | |
| SCHEMBL22467416 | 0.82 | CDK2 (0.71) | CDK2CCNA1FLT3PBKTRPA1 | |
| SCHEMBL22466906 | 0.81 | CDK2 (0.50) | CDK2CCNA1FLT3PBKTRPA1 | |
| SCHEMBL30490738 | 0.81 | CDK2 (0.50) | CDK2CCNA1FLT3PBKTRPA1 | |
| SCHEMBL22478032 | 0.81 | CDK2 (0.52) | CDK2CCNA1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371420-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2021-12-02 | — | — | US | disclosed |
| US-11040973-B2 | Inhibitors of kinase networks and uses thereof | PURDUE RESEARCH FOUNDATION | 2021-06-22 | — | — | US | disclosed |
| US-20200308173-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308173-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | KDM1B, JMJD6, KDM1A | CDK2 308/4885CCNA1 2225/4885FLT3 556/4885 |
| US-11040973-B2 | Inhibitors of kinase networks and uses thereof | KDM1B, JMJD6, KDM1A | CDK2 308/4885CCNA1 2225/4885FLT3 556/4885 |
| US-20210371420-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | KDM1B, JMJD6, KDM1A | CDK2 308/4885CCNA1 2225/4885FLT3 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.